📰
Breast cancer: the latest breakthroughs
Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.
🤖What changed
Written by AI from the evidence below, every point cited
2026-10-26
Adding pembrolizumab to standard chemotherapy markedly improves outcomes for early‑stage triple‑negative breast cancer.
- Pembrolizumab combined with carboplatin, paclitaxel and doxorubicin increased pathological complete response and event‑free survival in neoadjuvant and adjuvant treatment of triple‑negative breast cancer.
Higher pCR rates and longer EFS translate into a greater chance of cure for patients with this aggressive subtype. NCT03036488 - Tucatinib added to trastuzumab and pertuzumab prolonged progression‑free survival in metastatic HER2‑positive breast cancer.
Improved disease control offers patients a new targeted option after standard HER2 therapy. NCT05132582 - Trastuzumab deruxtecan, alone or sequenced with THP, achieved higher pCR than standard ddAC‑THP in HER2‑positive early breast cancer.
A more effective antibody‑drug conjugate may become a new neoadjuvant standard, reducing recurrence risk. NCT05113251 - Ribociclib plus letrozole improved progression‑free survival as first‑line therapy for HR+/HER2‑negative advanced breast cancer, and alpelisib plus fulvestrant benefited patients with PIK3CA‑mutated disease in the second line.
These results expand personalized endocrine‑targeted strategies for hormone‑driven cancers. NCT03439046 - Abemaciclib combined with fulvestrant extended overall survival after progression on prior CDK4/6 inhibitor therapy.
Provides a proven post‑CDK4/6 treatment option, addressing an unmet need in advanced disease. PMID:42926108 - Oral dexamethasone prophylaxis was non‑inferior to short‑course IV dexamethasone for preventing paclitaxel hypersensitivity.
Simplifies pre‑medication, improving patient convenience and reducing infusion‑center workload. NCT03598426
What to watch next
- Long‑term efficacy and quality‑of‑life outcomes from the accelerated 2‑week radiation schedule (NCT04175210)
- Results of capsaicin versus pregabalin for neuropathic pain after breast surgery (NCT03794388)
- Impact of hypofractionated post‑mastectomy radiation on recurrence rates (NCT03414970)
💛 Recent phase‑3 trials show that adding immunotherapy or newer targeted agents to standard chemotherapy can significantly improve cure rates and disease control. At the same time, simpler dosing regimens and supportive‑care strategies are being validated to make treatment easier and safer.
🤖Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use
HealthTeky